LEUKAPHERESIS COLLECTION OF WBC?S FROM NORMALS AND PARTICIPANTS WITH CANCER

通过白细胞分离术从正常人和癌症患者中收集白细胞

• 批准号: 7606715
• 负责人: Craig Lee Slingluff
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606715
• 关键词: Aliquot; Antigens; Biological Assay; Clinical Trials; Collection; Computer Retrieval of Information on Scientific Projects Database; Cytomegalovirus; Freezing; Funding; Grant; Human; Human Herpesvirus 4; Immune; Immune response; Immunologic Monitoring; Immunotherapeutic agent; Immunotherapy; Individual; Institution; Leukapheresis; Liquid substance; Lymphocyte; Malignant Neoplasms; Measures; Nitrogen; Participant; Pattern; Peptides; Population; Purpose; Research; Research Personnel; Resources; Running; Sampling; Source; Specimen; Standards of Weights and Measures; T-Lymphocyte; Testing; Time; Tumor Antigens; United States National Institutes of Health; Universities; Vaccines; Variant; Viral; Virginia; cancer type; design; influenzavirus; pathogen; response; vaccine efficacy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to use leukapheresis to collect lymphocytes from participants with cancer and normal donors to use as standards for assays analyzing the efficacy of vaccines in the University of Virginia Human Immune Therapy Center clinical trials. Lymphocytes from normal donors and participants with cancer will be frozen in aliquots and stored in liquid nitrogen until use. Upon thawing, lymphocytes from normal donors and participants with cancer will be tested as standards along with the vaccine trials participants' specimens. The control lymphocytes will be stimulated with lysates or peptides derived from common viral pathogens such as cytomegalovirus (CMV), Epstein-Barr virus (EBV) and influenza virus (FLU). Since most individuals have been exposed to these pathogens, an immune response can be measured. If the lymphocytes are obtained at one time from a single source, then a similar response pattern should be seen each time these standards are run. The standards will be compared to themselves in subsequent assays over time, to generate a coefficient of variation, in order to validate the immune monitoring assays. The specimens from participants with cancer may also be screened for the presence of T cells that are reactive against new tumor antigens that are identified in the lab. Having samples from participants with different cancers would enable the HITC lab to examine differences in pre-existing T-cell responses to the newly identified antigens, and may aid in the design of new immunotherapeutic vaccines for different types of cancer. Differences in immune competency between the two populations, normal donors and participants with cancer, may also be assessed. For this analysis, magnitude of immune responses to common viral pathogens would be compared between the two study groups.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是使用白细胞分离术从癌症患者和正常供体中收集淋巴细胞，用作弗吉尼亚大学人类免疫治疗中心临床试验中分析疫苗有效性的测定标准。 将来自正常供体和癌症受试者的淋巴细胞以等分试样冷冻并储存在液氮中直至使用。 解冻后，来自正常供体和癌症参与者的淋巴细胞将作为标准品与疫苗试验参与者的标本一起沿着进行检测。 对照淋巴细胞将用衍生自常见病毒病原体如巨细胞病毒（CMV）、EB病毒（EBV）和流感病毒（FLU）的裂解物或肽刺激。 由于大多数人都接触过这些病原体，因此可以测量免疫反应。 如果从单一来源一次获得淋巴细胞，则每次运行这些标准品时应观察到相似的响应模式。 在随后的试验中，随时间推移将标准品与自身进行比较，以生成变异系数，从而验证免疫监测试验。 来自癌症参与者的标本也可以筛查T细胞的存在，这些T细胞对实验室中鉴定的新肿瘤抗原具有反应性。 从患有不同癌症的参与者中获得样本将使HITC实验室能够检查预先存在的T细胞对新识别的抗原的反应的差异，并可能有助于设计针对不同类型癌症的新免疫疫苗。 还可以评估两个群体（正常供体和患有癌症的参与者）之间的免疫能力差异。 对于该分析，将比较两个研究组之间对常见病毒病原体的免疫应答的程度。